Dr. Michael Snyder, Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine & Track 5 Chair: "…the entire health care system seems totally broken. Nobody pays to keep people healthy....
Most of today's medical data are hidden in isolated databases, stored in systems that are often incompatible, and managed by proprietary software. This can slow down medical progress, as technologies that rely on these data cannot be used to their fullest potential to benefit elucidation...
Precision medicine brought hope to thousands of families coping with rare and deadly diseases. For the first time, gene therapies for disorders such as X-linked severe combined immunodeficiency (SCID, better known as the "bubble boy disease"), and spinal muscular atrophy (SMA) have shown remarkable safety...
Q: Cardiovascular disease, listed as the underlying cause of death, accounts for about 1 in 3 deaths in the US with coronary heart disease being the leading cause (43.8%), followed by stroke (16.8%), and heart failure (9.0%). To address this issue, it is necessary to...
Globally, healthcare companies have raised over 3,400 rounds this year and are on target to exceed 4,500 annually for the first time. Companies have raised over $37.5B through the first nine months of 2019, according to a CB Insights report....
I have gathered a few interesting recent research highlights about the human microbiome that I thought you might find interesting, see below....
Q: Nanopore technology has been touted as a convenient and versatile DNA detection platform, but it has yet to reach its potential. Why is that, and how is your platform different? A: Single solid-state nanopore technology has yet to reach its potential even though the initial...
I have gathered a few interesting recent research highlights about the human microbiome that I thought you might find interesting, see below....
Q: You recently raised $4.1 million in seed funding from Andreessen Horowitz and Felicis Ventures. What differentiates Genesis Therapeutics from the over 200 AI/ML drug development startups in this space? A: Genesis is unique in its groundbreaking deep learning technology, its synergy of machine learning (ML)...
Q: Success rates of clinical trials have not improved over the years despite the advances in biomedical knowledge. How can recent advances in artificial intelligence be used to improve trials success rates A: It is evident that we are not learning sufficiently from the many clinical...
